H., Mathers, C., Tuomilehto, J., Nag, S., Connolly, V., & King, H
According to FDA prescribing information, gallbladder-related adverse events occurred in clinical trials of semaglutide for weight management (Wegovy) at rates of 2.5% versus 1.0% with placebo, and for tirzepatide (Zepbound) at rates of 2.5% versus 1.0% with placebo
Their sales reps stopped replying to messages, stranding buyers who had already paid hundreds of dollars
If you do not experience an immediate reduction in your appetite, do not feel discouraged or assume the treatment is failing
When resuming after a dose hold, drop back to the previous dose level and maintain that level for an additional 4 weeks before attempting escalation again
Store the vial in the refrigerator, preferably in a dark bag, to minimize exposure to light and reduce degradation